In addition, it has been widely accepted that the degree of tumor infiltration with CD8+ T cells (Tumor-infiltrating lymphocytes, TILs) is also a favorable prognostic factor for tumor rejection and clinical efficacy of immunotherapy. The gene discussed is CD8A; the disease is neoplasm.